Phytochemicals targeting epidermal growth factor receptor (EGFR) for the prevention and treatment of HNSCC: A review

被引：1

作者：

Li, Shaling ^{[1
]}

Sun, Yongdong ^{[1
]}

机构：

[1] Southwest Med Univ, Affiliated Hosp Tradit Chinese Med, Luzhou, Sichuan, Peoples R China

来源：

MEDICINE | 2023年 / 102卷 / 40期

关键词：

epidermal growth factor receptor (EGFR); head and neck squamous cell carcinoma (HNSCC); phytochemicals; SQUAMOUS-CELL CARCINOMA; HUMAN HEAD; SIGNALING PATHWAYS; DOWN-REGULATION; BREAST-CANCER; ORAL-CANCER; NECK; DIHYDROARTEMISININ; HONOKIOL; RISK;

D O I：

10.1097/MD.0000000000034439

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Head and neck squamous cell carcinoma (HNSCC) develops from the mucosal epithelium of the oral cavity, pharynx, and larynx, and is the most common malignancy of the head and neck, the incidence of which continues to rise. The epidermal growth factor receptor is thought to play a key role in the pathogenesis of HNSCC. Inhibition of epidermal growth factor receptor has been identified as an effective target for the treatment of HNSCC. Many phytochemicals have emerged as potential new drugs for the treatment of HNSCC. A systematic search was conducted for research articles published in PubMed, and Medline on relevant aspects. This review provides an overview of the available literature and reports highlighting the in vitro effects of phytochemicals on epidermal growth factor in various HNSCC cell models and in vivo in animal models and emphasizes the importance of epidermal growth factor as a current therapeutic target for HNSCC. Based on our review, we conclude that phytochemicals targeting the epidermal growth factor receptor are potentially effective candidates for the development of new drugs for the treatment of HNSCC. It provides an idea for further development and application of herbal medicines for cancer treatment.

引用

页数：9

共 105 条

[1] Resumption of Immune Checkpoint Inhibitor Therapy After Immune-Mediated Colitis [J].

Abu-Sbeih, Hamzah ;

Ali, Faisal S. ;

Naqash, Abdul Rafeh ;

Owen, Dwight H. ;

Patel, Sandipkumar ;

Otterson, Gregory A. ;

Kendra, Kari ;

Ricciuti, Biagio ;

Chiari, Rita ;

De Giglio, Andrea ;

Sleiman, Joseph ;

Funchain, Pauline ;

Wills, Beatriz ;

Zhang, Jiajia ;

Naidoo, Jarushka ;

Philpott, Jessica ;

Gao, Jianjun ;

Subudhi, Sumit K. ;

Wang, Yinghong .

JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (30) :2738-+

[2] Pharmacological Strategies to Retard Cardiovascular Aging [J].

Alfaras, Irene ;

Di Germanio, Clara ;

Bernier, Michel ;

Csiszar, Anna ;

Ungvari, Zoltan ;

Lakatta, Edward G. ;

de Cabo, Rafael .

CIRCULATION RESEARCH, 2016, 118 (10) :1626-1642

[3] Deguelin Potentiates Apoptotic Activity of an EGFR Tyrosine Kinase Inhibitor (AG1478) in PIK3CA-Mutated Head and Neck Squamous Cell Carcinoma [J].

Baba, Yuh ;

Maeda, Toyonobu ;

Suzuki, Atsuko ;

Takada, Satoshi ;

Fujii, Masato ;

Kato, Yasumasa .

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2017, 18 (02)

[4] Deguelin Induces Apoptosis by Targeting Both EGFR-Akt and IGF1R-Akt Pathways in Head and Neck Squamous Cell Cancer Cell Lines [J].

Baba, Yuh ;

Fujii, Masato ;

Maeda, Toyonobu ;

Suzuki, Atsuko ;

Yuzawa, Satoshi ;

Kato, Yasumasa .

BIOMED RESEARCH INTERNATIONAL, 2015, 2015

[5] The epidermal growth factor receptor family [J].

Bazley, LA ;

Gullick, WJ .

[6] Afatinib versus placebo as adjuvant therapy after chemoradiation in a double-blind, phase III study (LUX-Head & Neck 2) in patients with primary unresected, clinically intermediate-to-high-risk head and neck cancer: study protocol for a randomized controlled trial [J].

Burtness, Barbara ;

Bourhis, Jean P. ;

Vermorken, Jan B. ;

Harrington, Kevin J. ;

Cohen, Ezra E. W. .

TRIALS, 2014, 15

[7] Triple Therapy with MerTK and PD1 Inhibition Plus Radiotherapy Promotes Abscopal Antitumor Immune Responses [J].

Caetano, Mauricio S. ;

Younes, Ahmed I. ;

Barsoumian, Hampartsoum B. ;

Quigley, Michael ;

Menon, Hari ;

Gao, Chan ;

Spires, Thomas ;

Reilly, Timothy P. ;

Cadena, Alexandra P. ;

Cushman, Taylor R. ;

Schoenhals, Jonathan E. ;

Li, Ailin ;

Quynh-Nhu Nguyen ;

Cortez, Maria Angelica ;

Welsh, James W. .

CLINICAL CANCER RESEARCH, 2019, 25 (24) :7576-7584

[8] Dihydroartemisinin overcomes the resistance to osimertinib in EGFR-mutant non-small-cell lung cancer [J].

Cai, Xueting ;

Miao, Jing ;

Sun, Rongwei ;

Wang, Sainan ;

Molina-Vila, Miguel Angel ;

Chaib, Imane ;

Rosell, Rafael ;

Cao, Peng .

PHARMACOLOGICAL RESEARCH, 2021, 170

[9] Epidermal growth factor receptor as a major anticancer drug target [J].

Caponigro, Francesco ;

Milano, Amalia ;

Ottaiano, Alessandro ;

Iaffaioli, Rosario Vincenzo .

EXPERT OPINION ON THERAPEUTIC TARGETS, 2006, 10 (06) :877-888

[10] Osimertinib and dihydroartemisinin: a novel drug combination targeting head and neck squamous cell carcinoma [J].

Chaib, Imane ;

Cai, Xueting ;

Llige, David ;

Santarpia, Mariacarmela ;

Jantus-Lewintre, Eloisa ;

Filipska, Martyna ;

Pedraz, Carlos ;

Cui, Jean ;

Yang, Jie ;

Miao, Jing ;

Sun, Rongwei ;

Paulina Bracht, Jillian Wilhelmina ;

Ito, Masaoki ;

Codony-Servat, Jordi ;

Karachaliou, Niki ;

Aguilar, Andres ;

Rosell, Rafael ;

Cao, Peng .

ANNALS OF TRANSLATIONAL MEDICINE, 2019, 7 (22)

← 1 2 3 4 5 6 7 8 9 10 →